en · de · es · fr · pt
semaglutide-notes.peptides1004.com › Info › Background And Molecular Profile — Explained

Background And Molecular Profile — Explained

By Editorial Desk · published 2025-07-07 · last reviewed 2025-08-05 · Info

This is a working overview of incretin hormone, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Profile

Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.

The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.

Peptide Background and Receptor Mechanism

Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.

The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.

Semaglutide at a glance

PropertyValueNotes
Molecular formula (free base)C187H291N45O59Approximate; salt and hydrate forms differ
Molecular weight~4113.6 DaVaries with counterion and hydration
AppearanceWhite to off-white powderLyophilized research material
Solubility classFreely soluble in waterAs formulated; native peptide less stable near neutral pH
Typical storage2 to 8 degrees CelsiusProtect from light; avoid repeated freeze-thaw

Background and Molecular Design

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

Related pages on this site

Semaglutide Structure and Receptor Mechanism

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Background and Mechanism of Action

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Mechanism and Pharmacological Class

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Supporting material

== Research == Sandra Pizzarello's research over the last forty years involved the analysis of organic compounds in several carbonaceous chondrites, particularly molecular, chiral, and isotopic characterization of amino acids. Because the formation of these organic-rich meteorites pre-date the origin of life, they had been under investigation as potential sites of primal organic compounds which could shed light on abiogenesis, specifically the origin of biological homochirality. Such studies, however, had been inconclusive until 1997 when Cronin and Pizzarello detected 7-9% L-enantiomeric excesses of three abiological amino acids while analyzing the Murchison meteorite. Given Earth's history of meteoric impacts and the observation that meteors contain an excess of the biologically relevant L-stereoisomer of certain amino acids, Pizzarello studied the effect of meteoritic amino acids in enantiomeric excess on the formation of other biological molecules. In one study, Pizzarello found that nonracemic solutions of abiological isovaline and proteinogenic alanine can direct the condensation of glycolaldehyde to produce nonracemic solutions of threose and erythrose via an aldol reaction concluding that amino acids can act as asymmetric catalysts in carbohydrate synthesis. These findings support the origin of life hypothesis that homochirality originated prior to life and from extraterrestrial origins. However, Pizzarello's theoretical inquiries into cosmochemical evolution remain debated based on suspect analytical evidence of meteoritic enantiomeric excesses.

The synthesis of fentanyl and its analogues are illustrated in these skeletal diagrams. The synthesis of fentalogs is done by reacting the ring structure as a base, 4-ANPP also called 4-anilino-N-phenethylpiperidine and despropionylfentanyl. 4-ANPP acts as a base because of its two amine nitrogens, the secondary amine acts as a base to react with an organic acid which condenses into an amide. Depending on the organic acid used in the amide condensation, different analogues of fentanyl will be produced. To help align this phenomenon in the eyes of chemists, we have numerated the precursor 4-ANPP with a [0.], and then the reactions synthesizing fentanyl, acetylfentanyl, butyrylfentanyl, and benzoylfentanyl with a [1.], [2.], [3.], and [4.] respectively. To further aid in the chemical pedagogy we have aligned each number with a reaction number -> precursor -> product system that follows the following scheme: EXAMPLE: reaction number -> precursor -> product [compound name] 1 -> α -> a [fentanyl] 2 -> β -> b [acetylfentanyl] 3 -> γ -> c [butyrylfentanyl] 4 -> δ -> d [benzoylfentanyl] Using the above scheme, a chemist can quickly extrapolate the reactions necessary for other fentanyl analogues with more complex organic acids, such as cyclopropryl fentanyl or cyclopentyl fentanyl, or any other fentanyl analogue derived from a reaction of 4-ANPP with a novel organic acid.

G banding Also Giemsa banding or G-banding. A technique used in cytogenetics to produce a visible karyotype by staining the condensed chromosomes with Giemsa stain. The staining produces consistent and identifiable patterns of dark and light "bands" in regions of chromatin, which allows specific chromosomes to be easily distinguished.

=== Modeling of side-chain conformations === Accurate packing of the amino acid side chains represents a separate problem in protein structure prediction. Methods that specifically address the problem of predicting side-chain geometry include dead-end elimination and the self-consistent mean field methods. The side chain conformations with low energy are usually determined on the rigid polypeptide backbone and using a set of discrete side chain conformations known as "rotamers". The methods attempt to identify the set of rotamers that minimize the model's overall energy. These methods use rotamer libraries, which are collections of favorable conformations for each residue type in proteins. Rotamer libraries may contain information about the conformation, its frequency, and the standard deviations about mean dihedral angles, which can be used in sampling. Rotamer libraries are derived from structural bioinformatics or other statistical analysis of side-chain conformations in known experimental structures of proteins, such as by clustering the observed conformations for tetrahedral carbons near the staggered (60°, 180°, −60°) values. Rotamer libraries can be backbone-independent, secondary-structure-dependent, or backbone-dependent. Backbone-independent rotamer libraries make no reference to backbone conformation, and are calculated from all available side chains of a certain type (for instance, the first example of a rotamer library, done by Ponder and Richards at Yale in 1987).

== Poiseuille's equation for an ideal isothermal gas == For a compressible fluid in a tube the volumetric flow rate Q(x) and the axial velocity are not constant along the tube; but the mass flow rate is constant along the tube length. The volumetric flow rate is usually expressed at the outlet pressure. As fluid is compressed or expanded, work is done and the fluid is heated or cooled. This means that the flow rate depends on the heat transfer to and from the fluid. For an ideal gas in the isothermal case, where the temperature of the fluid is permitted to equilibrate with its surroundings, an approximate relation for the pressure drop can be derived. Using ideal gas equation of state for constant temperature process (i.e.,

Sources: en.wikipedia.org

Notes from published material

On 24 June 2013, while the Essendon Football Club was being investigated by the Australian Sports Anti-Doping Authority (ASADA) over the legality of its supplements program during the 2012 AFL season, Watson admitted on the Fox Footy program On the Couch that he believed he was given the substance AOD-9604 during the 2012 season with the assistance of the club. The World Anti-Doping Agency (WADA) released a statement clarifying that AOD-9604 fell into the "S0. Non-Approved Substances" category in their List of Prohibited Substances and Methods. ASADA also stated that the use of AOD-9604 is prohibited for use by athletes in any circumstances. During the investigation, Watson was among the thirty-four present and former Essendon players issued show cause notices by ASADA and infraction notices by the AFL, alleging the use of the banned peptide Thymosin beta-4 during the 2012 season. On 31 March 2015, the AFL Anti-Doping Tribunal found all thirty-four players not guilty of all charges. In January 2016, following an appeal by WADA against the AFL Tribunal's not-guilty finding, Watson, along with the other thirty-three players, had their not-guilty verdict overturned. All thirty-four players were suspended for two years, backdated to November 2016, causing him to miss the entire 2016 AFL season. As Watson had won the 2012 Brownlow Medal, during the season that the supplements program took place, the AFL Commission reviewed the award.

Carl Gustav Jung was born 26 July 1875 in Kesswil, in the Swiss canton of Thurgau, as the first surviving son of Paul Achilles Jung (1842–1896) and Emilie Jung (née Preiswerk; 1848–1923). His birth was preceded by two stillbirths and that of a son named Paul, born in 1873, who survived only a few days. Paul Jung, Carl's father, was the youngest son of a noted German-Swiss physician and professor of medicine at Basel, Karl Gustav Jung (1794–1864). Karl Jung became Rector of Basel University and Master of the Swiss Lodge of Freemasons. It was rumoured that he was the illegitimate son of Goethe, but this is likely a legend. Paul Jung was a rural pastor in the Swiss Reformed Church.Jung considered his father reliable, but weak and powerless. Emilie Preiswerk, Carl's mother, grew up in a large family whose Swiss roots went back five centuries. She was the youngest child of a distinguished Basel churchman and academic, Samuel Preiswerk (1799–1871), and his second wife. Samuel Preiswerk was an Antistes (the title given to the head of the Reformed clergy in the city) as well as a Hebraist, author, and editor, who taught Paul Jung as his professor of Hebrew at Basel University. He was an early advocate of Zionism and was interested in the occult. Eight of Carl Jung's uncles were also clergymen.

Many other organisms obtained chloroplasts from the primary chloroplast lineages through secondary endosymbiosis—engulfing a red or green alga with a primary chloroplast. These chloroplasts are known as secondary plastids. As a result of the secondary endosymbiotic event, secondary chloroplasts have additional membranes outside of the original two in primary chloroplasts. In secondary plastids, typically only the chloroplast, and sometimes its cell membrane and nucleus remain, forming a chloroplast with three or four membranes—the two cyanobacterial membranes, sometimes the eaten alga's cell membrane, and the phagosomal vacuole from the host's cell membrane. The genes in the phagocytosed eukaryotes nucleus are often transferred to the secondary host's nucleus. Cryptomonas and chlorarachniophytes retain the phagocytosed eukaryotes nucleus, an object called a nucleomorph, located between the second and third membranes of the chloroplast. All secondary chloroplasts come from green and red algae. No secondary chloroplasts from glaucophytes have been observed, probably because glaucophytes are relatively rare in nature, making them less likely to have been taken up by another eukaryote. Still other organisms, including the dinoflagellates Karlodinium and Karenia, obtained chloroplasts by engulfing an organism with a secondary plastid. These are called tertiary plastids.

Whey protein is commonly marketed as a dietary supplement, and various health claims have been attributed to it in the alternative medicine community. Although whey proteins are responsible for some milk allergies, the major allergens in milk are the caseins. Whey is the primary ingredient in most protein powders, which are used primarily by athletes and bodybuilders to obtain the necessary amounts of protein for muscle building/maintenance on a daily basis. Whey protein has a high level of leucine, one of the three branched-chain amino acids, making it ideal for muscle growth and repair. Whey is pasteurized to assure that no harmful bacteria are breeding in the liquid. It is heated to 70–80 °C (158–176 °F) and is then cooled back down to 4 °C (39 °F). Studies have shown that this process of using extreme temperatures eliminates 99.7% of bacteria without coagulating the protein into a solid mass. Next, the whey must be filtered, and so is loaded into a massive web of ceramic filters and stainless steel turbines. These machines work to separate out the lactose as well as the fats, leaving a liquid of 90% whey protein. Hydrolysates are whey proteins that are predigested and partially hydrolyzed for the purpose of easier metabolizing, but their cost is generally higher. Highly hydrolysed whey may be less allergenic than other forms of whey, due to the fact that the short chain peptides obtained by hydrolysis are less antigenic, because of the elimination of sequential epitopes.

===== Translational control of cellular iron ===== Although some control exists at the transcriptional level, the regulation of cellular iron levels is ultimately controlled at the translational level by iron-responsive element-binding proteins IRP1 and especially IRP2. When iron levels are low, these proteins are able to bind to iron-responsive elements (IREs). IREs are stem loop structures in the untranslated regions (UTRs) of mRNA. Both ferritin and ferroportin contain an IRE in their 5' UTRs, so that under iron deficiency their translation is repressed by IRP2, preventing the unnecessary synthesis of storage protein and the detrimental export of iron. In contrast, TFR1 and some DMT1 variants contain 3' UTR IREs, which bind IRP2 under iron deficiency, stabilizing the mRNA, which guarantees the synthesis of iron importers.

Sources: en.wikipedia.org

Further detail

Serbia and Montenegro had an area of 102,350 square kilometres (39,518 sq mi), with 199 kilometres (124 mi) of coastline. The terrain of the two republics is extremely varied, with much of Serbia comprising plains and low hills (except in the more mountainous region of Kosovo and Metohija) and much of Montenegro consisting of high mountains. Serbia is entirely landlocked, with the coastline belonging to Montenegro. The climate is similarly varied. The north has a continental climate (cold winters and hot summers); the central region has a combination of a continental and Mediterranean climate; the southern region had an Adriatic climate along the coast, with inland regions experiencing hot, dry summers and autumns and relatively cold winters with heavy snowfall inland. Belgrade, with its population of 1,574,050, is the largest city in the two nations: and the only one of significant size. The country's other principal cities were Novi Sad, Niš, Kragujevac, Podgorica, Subotica, Pristina, and Prizren, each with populations of about 100,000–250,000 people.

The word Pseudomonas means "false unit", from the Greek pseudēs (Greek: ψευδής, false) and (Latin: monas, from Greek: μονάς, a single unit). The stem word mon was used early in the history of microbiology to refer to microorganisms and germs, e.g., kingdom Monera. The species name aeruginosa is a Latin adjective form derived from the noun aerūgō meaning verdigris ("copper rust"), here applied in reference to the blue-green (verdigris-like) colour seen in laboratory cultures of the species. This blue-green pigment is a combination of two secondary metabolites of P. aeruginosa, pyocyanin (blue) and pyoverdine (green), which impart the blue-green characteristic color of cultures.

Most of the proteins in food responsible for the immune reaction in coeliac disease are prolamins. These are storage proteins rich in proline (prol-) and glutamine (-amin) that dissolve in alcohols and are resistant to proteases and peptidases of the gut. Prolamins are found in cereal grains with different grains having different but related prolamins: wheat (gliadin), barley (hordein), rye (secalin) and oats (avenin).

== See also == Dark cell Epithelial-mesenchymal transition Epithelial polarity Glycocalyx Inner and outer enamel epithelium Iris pigment epithelium Neuroepithelial cell Retinal pigment epithelium Skin cancer Sulcular epithelium List of distinct cell types in the adult human body

The reference values vary across studies, ranging from > 25 cm/s to > 35 cm/s. Values above 35 cm/s indicate the absence of arterial disease, values below 25 cm/s indicate arterial insufficiency, and values of 25–35 cm/s are indeterminate because they are less specific (see image below). The data obtained should be correlated with the degree of erection observed. If the peak systolic velocities are normal, the final diastolic velocities should be evaluated, those above 5 cm/s being associated with venogenic ED.

Sources: en.wikipedia.org

Frequently asked questions

What is the relationship between semaglutide and native GLP-1?

It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.

Does the oral form work the same way as the injectable form?

Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.

Is the peptide naturally present in the human body?

No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.

How does semaglutide differ from native GLP-1?

Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.

Network